Trial
NCT00958633
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of British Columbia
Collaborators
Canadian Institutes of Health Research (CIHR); GlaxoSmithKline; Lundbeck Canada Inc.; Lupin Limited
Condition
Bipolar I Disorder
Intervention
Escitalopram
Why stopped
Recruitment was stopped before the planned sample size was reached owing to the Covid-19 pandemic and expiration of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-15